Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Intellia Therapeutics (NTLA) Return on Assets: 2016-2025

Historic Return on Assets for Intellia Therapeutics (NTLA) over the last 10 years, with Sep 2025 value amounting to -0.49%.

  • Intellia Therapeutics' Return on Assets fell 8.00% to -0.49% in Q3 2025 from the same period last year, while for Sep 2025 it was -0.49%, marking a year-over-year decrease of 8.00%. This contributed to the annual value of -0.39% for FY2024, which is 6.00% down from last year.
  • Intellia Therapeutics' Return on Assets amounted to -0.49% in Q3 2025, which was up 2.75% from -0.50% recorded in Q2 2025.
  • Over the past 5 years, Intellia Therapeutics' Return on Assets peaked at -0.20% during Q4 2021, and registered a low of -0.50% during Q2 2025.
  • Its 3-year average for Return on Assets is -0.39%, with a median of -0.39% in 2024.
  • In the last 5 years, Intellia Therapeutics' Return on Assets rose by 12bps in 2021 and then declined by 16bps in 2022.
  • Over the past 5 years, Intellia Therapeutics' Return on Assets (Quarterly) stood at -0.20% in 2021, then declined by 14bps to -0.35% in 2022, then declined by 2bps to -0.37% in 2023, then declined by 5bps to -0.41% in 2024, then dropped by 8bps to -0.49% in 2025.
  • Its last three reported values are -0.49% in Q3 2025, -0.50% for Q2 2025, and -0.46% during Q1 2025.